Karolinska Institutet
Stockholm, 17177, Sweden
NCT Number: NCT05817188
Dementia creates a great personal and societal burden and there are currently no treatments to stop memory loss. Many patients with dementia take medications to treat other conditions, e.g. high blood pressure and cholesterol. Some of these medications may have central effects on the pathophysiological processes leading to dementia.
Medication repurposing is a cost and time-effective way to discover new treatments. Swedish registers are a unique tool to detect medication candidates for repurposing. The Swedish Dementia Registry (SveDem) has >100000 patients and ca. 144000 measures of cognition over time (measured with the Mini-Mental State Examination-MMSE), making it perfect to examine whether certain medications are associated with less cognitive decline in patients with dementia. Cholesterol and kidney function affect treatment and cognition and are available for 25000 patients. The investigators propose a study combining traditional cohort studies and newer artificial intelligence (machine learning) techniques to detect medications associated with slower cognitive decline in patients from SveDem. The investigators will test pre-specified hypotheses since the investigators suspect specific medications are better candidates to prevent cognitive decline, but the investigators will also let the machine learning algorithms explore the data to find associations that the investigators do not suspect in advance. Finally, the candidate medications will be tested in animal and cellular models to determine the mechanisms of their effects.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
Stockholm, 17177, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All patients with dementia registered in SveDem.
Exclusion criteria
Lack of Swedish personal identification number or coordination number.
No intervention was applied
Time frame: Through study completion, at least 1 year
The data on cognitive decline will be assessed by Mini Mental State Examination (MMSE) score. The MMSE score ranges from 0 and 30. Higher scores mean a better outcome.
Time frame: Through study completion, at least 1 year
Data will be obtained from the social services registry.
Time frame: Through study completion, at least 1 year
Data about date and cause(s) of death will be collected from The Cause of Death Register.
Karolinska Institutet
Other
Translational Identification of Medication Repurposing Candidates to Slow Cognitive Decline in Dementia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03923712
Alzheimer Dementia, Alzheimer Disease
Cadiz, Spain
View Trial DetailsNCT03926520
Aberrant Motor Behavior in Dementia, Agitation,Psychomotor
Atlanta, Georgia, United States
View Trial DetailsNCT03875638
Alzheimer Dementia, Alzheimer Disease
Boston, Massachusetts, United States
View Trial DetailsNCT03537729
Age-related Memory Disorders, Alzheimer Dementia
Allendale, Michigan, United States
View Trial Details